Portal Hypertension Bleeding: Risk Stratification, Diagnosis, and Management

Portal Hypertension Bleeding: Risk Stratification, Diagnosis, and Management

Summary of Medical Lecture by Annalisa Berzigotti

1. Main Clinical Topics Discussed

• Definition, pathophysiology, and classification of portal hypertension (PH)
• Staging and prognosis of cirrhosis (compensated vs. decompensated)
• Invasive and non-invasive diagnostic approaches to PH
• Risk stratification for variceal bleeding and clinical decompensation
• Baveno VI/VII non-invasive test (NIT) criteria and their clinical application
• Special populations: obese patients (MASLD/NASH), post-SVR hepatitis C

2. Key Learning Points, Guidelines, and Recommendations

Pathophysiology

• Portal hypertension arises from increased resistance to portal flow (Ohm's Law: Pressure = Resistance × Flow)
• >90% of cases in the Western world are caused by chronic liver disease/cirrhosis
• Sinusoidal fibrosis is the primary driver of increased resistance

Cirrhosis Staging and Prognosis

• Compensated cirrhosis: Median survival >12 years
• Decompensated cirrhosis (ascites, variceal hemorrhage, hepatic encephalopathy): Median survival reduced to 2–4 years
• Portal hypertension is the principal driver of progression from compensated to decompensated disease
• In decompensated patients, clinically significant PH (CSPH) is assumed — further diagnostic workup to confirm PH is unnecessary

Gold Standard: Hepatic Venous Pressure Gradient (HVPG)

• Measured via balloon catheter inserted through peripheral vein (jugular, femoral, or antecubital)
• HVPG = Wedge pressure − Free hepatic venous pressure
• Key threshold: HVPG ≥10 mmHg defines Clinically Significant Portal Hypertension (CSPH)
• HVPG is a strong, independent prognostic marker for:

- Clinical decompensation

- Variceal development and bleeding

- Overall mortality

Non-Invasive Tests (NITs)

• Liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE) is the primary NIT
• LSM correlates well with HVPG up to ~10–12 mmHg; above this, hyperdynamic flow reduces accuracy
• Additional modalities: point shear-wave elastography, 2D shear-wave elastography, MRI elastography

Baveno VI Criteria (variceal screening)

• LSM <20 kPa AND platelet count >150 × 10⁹/L → can safely rule out high-risk varices, avoiding endoscopy
• Confirmed by multiple studies and meta-analyses across liver disease etiologies

Baveno VII "Rule of 5" (VCTE-based)

• LSM <15 kPa + normal platelets → rules out CSPH
• LSM >25 kPa (non-obese, non-MASLD) → confirms CSPH
• For point/2D shear-wave elastography: analogous "Rule of 4" (slightly different kPa thresholds)

Special Populations

• Obese/MASLD patients: LSM thresholds less reliable; use the ANTICIPATE-NASH model (incorporates BMI + platelet count + LSM); validated in two independent cohorts
• Post-SVR hepatitis C: LSM decreases rapidly after viral clearance (reflects reduced inflammation, not fibrosis regression); standard thresholds do not apply directly, but LSM >25 kPa post-SVR still indicates residual PH risk

3. Specific Clinical Data, Statistics, and Study Results Cited

• >80% of deaths in advanced chronic liver disease are attributable to PH complications
• ANTICIPATE study (multicenter): Validated combination of LSM + spleen size + platelet count for CSPH prediction
• Baveno VI meta-analysis: LSM <20 kPa + platelets >150 × 10⁹/L safely avoids end